OVERVIEW & OBJECTIVE
The Vita D'or European Bioprocessing Excellence Awards 2026 celebrate outstanding achievements across bioprocessing, bioformulation, ADC manufacturing, outsourcing, and biomanufacturing innovation.
We're celebrating:
- Biopharma companies driving breakthroughs in process development, manufacturing, and commercialisation
- CDMOs, CMOs, CROs, and technology providers accelerating scale, quality, and operational excellence
- Collaborative partnerships that are redefining what's possible in biomanufacturing
The Awards will be presented alongside the Biomanufacturing Leaders' Summit, bringing together the communities behind Biologics Manufacturing UK, BioFormulate Live, and BioOutsourcing Europe for an evening dedicated to recognising excellence, innovation, and industry impact.
HOW DOES IT WORK?
The organising committee of the Vita D'or European Bioprocessing Excellence Awards 2026 will call for nominations from the European biopharma community for various award categories. All entries and nominations will be considered and submitted to the judging panel. Based on the number of nominations and the assessment process, the top 5–7 entries in each category will be shortlisted. From these top 5–7 entries, the award winner will be determined by voting results from the European biopharma community.
CONCEPT & CRITERIA
2026 AWARDS TIMELINE
WHY OUR AWARDS?
IMAPAC has been serving the Biopharma industry for the past 14 years. We pride ourselves in organising conferences in a revolutionising industry and providing new opportunities for those who participate.
CRITERIA FOR NOMINATION
- The organisation should be involved in biopharmaceutical development, manufacturing, formulation, ADCs, or outsourcing.
- The organisation should have operations, clients, or demonstrated impact in Europe, or at least have solutions/technology/pipeline that can be implemented for the European market.
- The organisation should have displayed significant developments in the past few years.
CRITERIA TO WIN THE AWARDS
Based on the number of nominations and assessment, the top 5–7 entries under each category will be shortlisted. From these top 5–7 entries, the award winner will be determined by voting results from the European biopharma community. Organisations with the most votes will win the award in their respective category.
